Video

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, professor, D. B. Lane Cancer Research Distinguished Professor, section chief of Chronic Lymphocytic Leukemia, center medical director, Department of Leukemia, Division of Cancer Medicine, and executive medical director, The University of Texas MD Anderson Cancer Center, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

In CLL, CAR T-cell therapy is investigational, says Wierda, whereas in acute lymphoblastic leukemia (ALL) and diffuse large B-cell leukemia there are 2 FDA-approved products that are available for use.

In the ongoing phase I/II TRANSCEND trial, investigators are evaluating lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and CLL. Early data from the trial showed a 43.8% complete response rate in patients with heavily pretreated CLL, which is lower than what has been reported in ALL, says Wierda. As such, further investigation into CD19-targeted CAR T cells is needed in order to maximize their benefit in CLL, Wierda concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center